xxxxiiiiiixxxxxiiiiixiixixix
22nd Century Group
Reduced Nicotine · Regulatory Leadership
XXII
Nasdaq Listed
May 2026 · Investor Overview
The Regulatory Opportunity
Built for the mandate.
Not running from it.
In a world where tobacco regulation is only tightening, most companies are playing defense. 22nd Century Group is playing offense — with a product that doesn't just survive the regulatory tide, it was built for it.
VLN® cigarettes contain approximately 95% less nicotine than conventional cigarettes — validated by clinical science and already authorized by the FDA. While Big Tobacco lobbies against the FDA mandate, XXII is the mandate.
VLN® isn't a harm-reduction compromise. It's the market leader in an entirely new category — one the FDA is actively pushing the industry toward.
Content Category
Conventional Cigarettes
by End of 2026
Proven Science, Live Product
- Clinical validation in market — not a pipeline promise
- FDA-authorized and commercially available today
- VLN® partner brand program accelerating reach
Growth Engine in Motion
- Portfolio built for cross-sell and gradual expansion
- Roadmap extends through 2026 into 2027
- Full alignment with FDA's low nicotine mandate
R&D That Doesn't Stop
- Ongoing development in low-nicotine crop strains
- Reduced-nicotine product pipeline expanding
- Growth through licensing and strategic partnerships
Path to Profitability
- Dual-track portfolio: VLN® + Partner Brand high-margin products
- Scaling distribution and sell-through as key levers
FDA Mandatory Low-Nicotine Rule
If and when the FDA finalizes a low-nicotine product standard, XXII becomes the only major player with an already-authorized, commercially available product. First-mover positioning could be decisive.
Distribution Scale Milestones
Expanding retail footprint and sell-through velocity are the company's stated key success metrics. Watch for distribution announcements and volume data through H2 2026.
VLN® Partner Brand Growth
The licensing and co-branding model allows XXII to multiply reach without proportional capex. New partnership announcements signal accelerating commercialization.
5,000 Locations by End of 2026
The company plans to expand VLN® distribution to more than 5,000 retail locations across the U.S. by year-end — increasing national availability and product adoption at scale.
The Only Cigarette
The FDA Already Authorized.
XXII is the true leader in the tobacco harm reduction movement with over 28 years under its belt. VLN® cigarettes deliver ~95% less nicotine than conventional cigarettes — validated by clinical science, recognized by the FDA and the World Health Organization.
While Big Tobacco lobbies against the FDA mandate, 22nd Century Group is the mandate. Their 60,000 sq ft facility in Mocksville, NC has the capacity to produce more than 45 million cartons annually. Revenues topped $17.5M in 2025, with rapid expansion planned for 2026.
The Opportunity
A $109B Industry Ready for Disruption
There are 28.8 million active smokers in the U.S. Every day, 1,315 of them die from smoking-related conditions — nearly 480,000 deaths annually. Smoking kills more Americans each year than alcohol, drugs, car accidents, and gun violence combined. The tobacco industry generates $109B in annual sales, with $83B coming directly from cigarettes.
Many studies show at least 70% of smokers want to quit but can't — that is a massive, addressable market. The question has never been whether people will smoke; it's whether they'll have access to a meaningfully less harmful way to do it. VLN® is the answer.
Regulatory Position
FDA Acceptance Is the Moat
22nd Century just announced the FDA has formally accepted its MRTP renewal applications for scientific review — a critical milestone that keeps VLN® on track to maintain its unique authorized modified risk marketing claims beyond the December 2026 expiration date. A 2024 real-world study of 400+ participants showed a 40% reduction in daily cigarette consumption over 12 weeks among VLN® users, giving the FDA a richer evidentiary record and investors more confidence in the renewal.
As the FDA moves toward implementing a nicotine standard that would force full-strength brands off the market or require reformulation, smokers will have no choice but to migrate toward reduced-nicotine options — and VLN® is the only combusted cigarette already authorized and waiting for them.
Recent Business Highlights
Execution in Motion
Pinnacle® VLN® now in over 2,000 stores across 20 states with in-store marketing and digital promotion programs
Achieved near-national level state authorizations to support expanded access to branded products
Completed product prototyping for 100mm format VLN® cigarettes ahead of planned PMTA authorization
Advanced multiple PMTAs across combustible products — diverse blends, sizes, and formats including filtered cigars
Leveraging VLN® tobacco supply and manufacturing under license to expand distribution and launch additional partner brands
New testing services agreement with NC State University advancing reduced nicotine platform R&D
Distribution Scale
5,000 Retail Locations by EOY 2026
Near-Term Catalysts
Watch These Closely
FDA Mandatory Low-Nicotine Rule
If finalized, XXII becomes the only player with an already-authorized, commercially available product. First-mover positioning could be decisive for the entire category.
MRTP Renewal Decision
FDA formally accepted renewal applications for scientific review. Maintaining authorized modified risk marketing claims beyond December 2026 is a key value inflection point.
VLN® Partner Brand Growth
The "VLN Inside" licensing and co-branding model multiplies reach without proportional capex. New partnership announcements signal accelerating commercialization.
100mm VLN® Product Launch
Prototyping complete. PMTA targeting approximately half of the ~$82B U.S. cigarette market — a massive addressable expansion for the reduced nicotine platform.
Why XXII
Four Reasons This Matters
01
Proven Science. Live Product.
Not a pipeline promise. VLN® is clinically validated, FDA-authorized, and on shelves today. The WHO has recognized the science. Multiple studies confirm the outcomes.
02
Unmatched Regulatory Moat
The only combusted cigarette ever authorized as a modified risk tobacco product. No competitor can replicate this overnight. Regulatory tailwinds are accelerating.
03
Scalable Licensing Model
The VLN® partner brand strategy lets XXII multiply distribution and revenue without proportional cost increases. Infrastructure for a whole new category.
04
Right Place, Right Time
The tobacco industry is restructuring into four lanes. XXII is uniquely positioned at the center of the harm reduction movement at exactly the right moment in regulatory history.
Latest News
Recent Announcements
Leadership
Management Team
Larry Firestone
Chief Executive Officer
40+ years of enterprise, operations, and financial management. Former CEO of Eastside Distilling (NASDAQ: EAST) and Qualstar Corporation (NASDAQ: QBAK). CFO of Advanced Energy Industries (NASDAQ: AEIS).
Robert Manfredonia
EVP of Sales
30 years in regulated consumer products sales and marketing. Deep expertise in distribution, volume growth, and brand building across spirits, wine, and beer channels.
Daniel A. Otto
Chief Financial Officer
Appointed CFO April 2024. 10+ years at Deloitte & Touche as Senior Manager. CPA with MBA from Niagara University. Oversees finance, SEC reporting, treasury, and IR.
Scott Marion
VP of Operations
20+ years in tobacco. Former head of Manufacturing & Supply Chain Finance at Reynolds American. MBA from Wake Forest University.
Jonathan Staffeldt
General Counsel
USC accounting degree, UCLA law degree. Background in M&A, contract negotiations, and debt/equity financings. Former GC at GVB Biopharma prior to 22nd Century acquisition.
Dr. Kimberly Farr, Ph.D.
Director of Science & Technology
Ph.D. in Biology. Leading research in non-GMO reduced nicotine tobacco plants since 2019. Applies computational and molecular biology to drive next-generation reduced-risk product development.